Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

por Taher, Ali, El-Beshlawy, Amal, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Hmissi, Abdel, Al Jefri, Abdullah
Publicado 2009

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study

por Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, Roubert, Bernard, El-Beshlawy, Amal
Publicado 2011

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration

por St Pierre, Tim G, El-Beshlawy, Amal, Elalfy, Mohsen, Al Jefri, Abdullah, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Taher, Ali
Publicado 2014

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

por Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal
Publicado 2011